US equities
|
TSLA
$359.83
▼-0.72%
MU
$896.20
▼-3.76%
NVDA
$216.50
▼-0.34%
AAPL
$345.64
▲+1.06%
SPCX
$145.29
▼-2.24%
SNDK
$1,335.63
▼-4.24%
META
$720.02
▼-2.27%
AMD
$541.37
▼-3.71%
TSLA
$359.83
▼-0.72%
MU
$896.20
▼-3.76%
NVDA
$216.50
▼-0.34%
AAPL
$345.64
▲+1.06%
SPCX
$145.29
▼-2.24%
SNDK
$1,335.63
▼-4.24%
META
$720.02
▼-2.27%
AMD
$541.37
▼-3.71%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Protagenic Therapeutics, Inc.
Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder
August 20, 2026
From
Protagenic Therapeutics, Inc.
Via
ACCESS Newswire
Tickers
PTIX
Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model
June 30, 2026
From
Protagenic Therapeutics, Inc.
Via
ACCESS Newswire
Tickers
PTIX
Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th
April 26, 2022
From
Protagenic Therapeutics, Inc.
Via
AccessWire
Tickers
PTIX